| 吉非替尼治疗21例晚期非小细胞肺癌疗效评价 |
| |
| 引用本文： | 张传红,王玉红.吉非替尼治疗21例晚期非小细胞肺癌疗效评价[J].中国医药导报,2010,7(33):133-134. |
| |
| 作者姓名： | 张传红 王玉红 |
| |
| 作者单位： | 江苏省镇江市中医院,江苏镇江212003 |
| |
| 摘 要： | 目的：探讨吉非替尼治疗难治性晚期非小细胞肺癌的疗效和不良反应。方法：选择晚期非小细胞肺癌患者21例,给予吉非替尼250 mg/d口服,评价其临床疗效。结果：总的疾病控制率为52.4%,患者中位生存期为272 d。结论：吉非替尼可改善晚期非小细胞肺癌患者的临床症状和生活质量,且耐受好。
|
| 关 键 词： | 吉非替尼 晚期非小细胞肺癌 靶向治疗 |
Efficacy of Gefitinib in the treatment of 21 patients with advanced non-small-cell lung cancer |
| |
| ZHANG Chuanhong,WANG Yuhong.Efficacy of Gefitinib in the treatment of 21 patients with advanced non-small-cell lung cancer[J].China Medical Herald,2010,7(33):133-134. |
| |
| Authors: | ZHANG Chuanhong WANG Yuhong |
| |
| Institution: | (Hospital of Traditional Chinese Medicine of Zhenjiang City,Jiangsu Province,Zhenjiang 212003,China) |
| |
| Abstract: | objective：To study the anti-tumor effect and toxicity of Gefitinib in the treatment of patients with advanced non-small-cell lung cancer（NSCLC）.Methods：21 advanced NSCLC patients were treated with Gefitinib orally 250 mg once per day.The response was evaluated.Results：The disease controlling rate was 52.4%.The median survival time was 272 days.Conclusions：Gefitinib may improve their symptoms and quality of life.It is tolerated by the patients with ad-vanced NSCLC. |
| |
| Keywords: | Gefitinib Non-small-cell lung cancer Target therapy |
| 本文献已被 维普 万方数据 等数据库收录！ |
